Switzerland is famous for watches, banks, chocolate and mountains. But one of the most important things it sells to the world comes in much smaller packages.
Pills. Vials. Injections. Vaccines. Biological medicines. And increasingly, highly sophisticated therapies developed from biotechnology.
The pharmaceutical industry has become one of the central pillars of the Swiss economy. In 2025, Swiss exports reached a record CHF 287 billion, with chemicals and pharmaceuticals accounting for CHF 152 billion — approximately 53% of all Swiss merchandise exports. The increase was particularly driven by serums and vaccines.
But those numbers conceal a much more interesting story.
- How did a small, landlocked country become a pharmaceutical superpower?
- How are medicines actually tested there?
- Who decides whether they can be sold?
- How are they promoted?
- Who pays for them?
And perhaps most importantly: Where does all the money go?
The Swiss pharmaceutical machine
Switzerland's pharmaceutical industry is not simply a collection of factories producing medicines. It is an interconnected ecosystem.
Research laboratories feed discoveries into biotechnology companies. Universities and hospitals provide scientific expertise and clinical research. Pharmaceutical companies finance development.
Contract research organisations conduct studies. Specialist manufacturers produce active pharmaceutical ingredients and finished medicines.
And multinational companies then sell the resulting products around the world.
The Swiss government describes chemicals and pharmaceuticals as Switzerland's leading export industry. The broader sector accounts for roughly 7% of Swiss GDP and employs more than 75,000 people directly, according to government information.
The pharmaceutical component has become particularly dominant.
According to Interpharma, the industry's trade association, pharmaceutical exports reached CHF 114.5 billion in 2024, equivalent to around 40.5% of Switzerland's total merchandise exports. The association reports pharmaceutical R&D expenditure of CHF 9.1 billion in 2024.
These figures show why pharmaceuticals are not merely another Swiss industry. They are central to the country's modern economic model.
From textile dyes to modern medicine
The story began in a rather unexpected place. During the 19th century, Swiss chemical companies were heavily involved in producing dyes for the textile industry.
The country lacked the huge coal reserves that powered Britain's industrial revolution, so competing through enormous quantities of basic industrial materials was difficult.
Instead, Swiss companies increasingly specialised in chemistry, precision and high-value products.
The chemical industry gradually moved towards increasingly sophisticated products, including serums, vaccines and medicines.
The Basel region became particularly important. And from this chemical foundation emerged companies that would eventually become global pharmaceutical giants.
One of them was Roche, founded in Basel in 1896. Another was Ciba-Geigy, which ultimately became part of Novartis.
Today, Roche and Novartis are among the world's largest pharmaceutical companies, while Switzerland also hosts companies such as Lonza, Debiopharm and a large network of biotechnology and specialist firms.
The result is a remarkable concentration of pharmaceutical expertise.
Switzerland's secret weapon: concentration
Switzerland's pharmaceutical success isn't just about having large companies. It is about having an entire ecosystem in close proximity. Basel is the obvious example.
Within a relatively small geographical area are pharmaceutical companies, biotech businesses, universities, research institutions, specialist manufacturers and service companies.
This creates what economists call an industrial cluster. A new pharmaceutical company doesn't have to build an entire ecosystem from scratch.
It can find:
- scientists
- engineers
- clinical researchers
- specialist manufacturers
- regulatory consultants
- lawyers
- patent specialists
- investors
- laboratories
- logistics companies
- hospitals
- research organisations
..all within the same broader ecosystem.
Government figures say Switzerland is home to approximately 1,000 companies operating in the chemicals and pharmaceuticals sector, with activity concentrated around Basel, Zurich, Zug and the Lake Geneva region.
The country also has a particularly strong biotechnology sector.
In 2025, Swiss biotechnology companies generated CHF 7.5 billion in revenue, while the sector attracted CHF 2.6 billion in investment.
The pharmaceutical industry therefore isn't a single machine. It is more like a network of interconnected machines.
But how does a drug actually become a drug?
This is where things become considerably more complicated. A pharmaceutical company can't simply discover a promising molecule and start selling it.
The journey from laboratory experiment to medicine can take a decade or more. Swissmedic, Switzerland's regulatory authority for therapeutic products, says the average journey from initial laboratory studies to the first prescription takes around 10–12 years.
The process broadly looks like this:
Discovery
↓
Laboratory research
↓
Preclinical testing
↓
Human clinical trials
↓
Regulatory assessment
↓
Marketing authorisation
↓
Pricing/reimbursement decisions
↓
Manufacturing
↓
Marketing and distribution
↓
Post-market safety monitoring
Every stage creates costs. But every successful stage also increases the potential value of the resulting intellectual property.
Stage One: discovering a medicine
It starts with biology. Scientists might identify a protein involved in cancer, a virus, or some other biological target.
Researchers then attempt to find something capable of changing that biological process.
That could be a conventional chemical compound, an antibody, a vaccine, or one of the newer classes of biological and cell-based treatments.
Thousands of possible compounds can be investigated. Most will fail.
This is one reason pharmaceutical companies spend so much on research. The successful medicine must effectively pay for the enormous amount of unsuccessful research that preceded it.
Stage Two: testing before humans
A potential medicine cannot simply be given to people.
Before human testing, researchers conduct laboratory and preclinical studies designed to investigate issues including toxicity, pharmacology and how the candidate behaves biologically.
The objective isn't to prove that the medicine definitely works in humans.
It is merely to establish whether there is enough evidence and justification to expose people to it. This distinction is important.
A drug candidate can look spectacular in laboratory experiments and still fail in humans. That happens frequently.
Stage Three: the human experiment
Eventually comes the point at which the candidate enters clinical trials. This is one of the most closely regulated parts of pharmaceutical development.
In Switzerland, clinical trials involving medicinal products generally require approval from both Swissmedic and the responsible Ethics Committee. The trial cannot begin until the required approvals have been obtained.
The trials progressively investigate questions such as:
- Is it safe?
- What dose should be used?
- Does it actually work?
- What side effects occur?
- How does it compare with existing treatments?
- Which patients benefit?
Clinical trials therefore aren't simply a single test. They are a series of increasingly sophisticated experiments.
Swissmedic: the gatekeeper
Swissmedic is Switzerland's regulatory authority for therapeutic products.
Its role extends across the life of a medicine. It assesses clinical trials, licenses manufacturing facilities, evaluates applications for marketing authorisation, and it monitors medicines after they reach the market.
When a pharmaceutical company eventually applies for authorisation, Swissmedic assesses the submitted evidence according to recognised criteria covering quality, safety and efficacy.
That means the company has to convince the regulator that the product:
- is manufactured to an acceptable standard
- has an acceptable safety profile
- provides evidence of effectiveness
- has benefits that justify its risks
This is an important distinction: Pharmaceutical companies develop and submit the evidence. The regulator decides whether the evidence satisfies the regulatory requirements.
Switzerland is also changing how quickly trials can begin
Switzerland introduced a fast-track pilot process in 2025 for certain clinical trials.
The system is intended for trials involving areas such as serious diseases with high unmet medical need, or investigational medicines already known to Swissmedic.
Under the pilot, qualifying applications can receive shorter processing targets — 20 days instead of 30 days for one category and 40 instead of 60 days for another.
That illustrates another part of Switzerland's pharmaceutical strategy. The country isn't simply trying to regulate medicines. It is also trying to remain attractive as a place to develop them.
What happens after approval?
Approval doesn't mean the job is finished. In many respects, it begins another phase.
Once a medicine is being prescribed to thousands or millions of people, rare side effects that weren't visible in clinical trials can emerge.
This is why pharmacovigilance exists.
Swissmedic conducts inspections of companies' pharmacovigilance systems and examines whether companies are complying with requirements for reporting adverse drug reactions.
The pharmaceutical lifecycle therefore looks more like:
Develop → test → approve → monitor → potentially modify or restrict
rather than:
Test → approve → finished.
So where does the money come from?
This is perhaps the most important part of the story. Pharmaceutical companies generally don't make their money from the initial scientific discovery.
They make it from commercialisation.
A company may spend billions developing a successful medicine.
If the medicine eventually receives approval, the company can sell it under the protection of intellectual property rights for a defined period.
That protection is fundamental to the pharmaceutical business model.
Switzerland's Federal Office of Public Health explicitly recognises the economic role of intellectual-property protection: pharmaceutical development can take 10–15 years from research through clinical trials and marketing, and intellectual-property rights provide a period in which companies can seek a return on their investment.
The basic commercial calculation is therefore:
Huge development cost + High probability of failure + Limited period of market exclusivity = Potentially very large revenues from successful medicines
The system is designed around the assumption that companies need the possibility of substantial returns to justify enormous investment and risk.
The extraordinary economics of a successful medicine
Consider Roche. In 2025, Roche reported: CHF 61.5 billion in total group sales. Of that: CHF 47.7 billion came from pharmaceuticals.
Roche reported CHF 21.8 billion in core operating profit and approximately CHF 12.2 billion in core R&D investment across the group. Pharmaceutical R&D expenditure alone was approximately CHF 10.4 billion.
This demonstrates the fundamental economics of the industry. A successful medicine can generate enormous revenues.
Roche's 2025 pharmaceutical sales were not generated primarily in Switzerland.
The United States alone accounted for CHF 25.4 billion of its pharmaceutical sales. Europe accounted for CHF 9.2 billion. Japan contributed CHF 2.9 billion. The rest of the international market contributed CHF 10.3 billion.
This is crucial to understanding Switzerland. It is the headquarters, research and production base for a globally oriented industry.
The market is the entire world.
Switzerland doesn't have to be the customer
This creates one of the country's most interesting economic advantages.
A Swiss pharmaceutical company can conduct research in Switzerland, manufacture a medicine there, and then sell it in America, Germany, Japan, Brazil or elsewhere.
The Swiss domestic market is tiny compared with the global pharmaceutical market.
That doesn't matter.
Switzerland has effectively positioned itself as a high-value production and intellectual-property centre rather than merely a large consumer market.
The same pattern appears across the country's economy.
Switzerland doesn't have millions of tonnes of raw materials, so it needs highly skilled people, capital, research institutions, intellectual property and access to international markets.
But who decides what the medicine costs?
Approval and pricing are separate questions. A medicine can be authorised but still face another hurdle before compulsory health insurance reimburses it.
Switzerland uses both an internal and external reference system when determining prices.
The external reference compares the medicine's price with prices in nine European reference countries:
Austria, Belgium, Denmark, Finland, France, Germany, the Netherlands, Sweden and the UK.
The internal comparison considers prices of existing medicines used for the same indication.
So the pharmaceutical company isn't simply able to announce: "This medicine costs CHF 100,000" and expect compulsory insurance to automatically pay it.
Pricing is part of a separate process.
Switzerland's unusual relationship with pharmaceutical prices
There is an obvious tension here. The pharmaceutical industry argues that research is expensive and that innovative medicines require substantial investment.
Health authorities, insurers and patients have a different concern: How much should society pay?
Switzerland's compulsory health insurance is legally structured around services being effective, appropriate and cost-effective. The authorities can therefore evaluate whether medicines and other healthcare interventions meet those requirements.
At the same time, pharmaceutical companies have strong incentives to protect the commercial value of their products.
This creates a permanent negotiation between innovation and affordability.
That argument is not unique to Switzerland. But because Switzerland is simultaneously a pharmaceutical headquarters, research centre and wealthy healthcare market, it has a particularly interesting position within it.
Could compulsory insurance payouts incentivise pharmaceuticals to 'price-rig'?
Yes — there is a plausible economic incentive here, but it needs to be described carefully.
The Swiss system creates conditions in which a pharmaceutical company can potentially obtain a relatively high price because the ultimate payer is largely insulated from the full price at the point of purchase. Although that is not the same as proving that pharmaceutical companies are price-rigging.
Under Switzerland's compulsory basic health insurance:
- a patient needs a medicine
- if it meets the reimbursement requirements, compulsory insurance covers it
- the pharmaceutical company negotiates with the authorities over the reimbursable price
- the FOPH establishes the maximum price for medicines on the Specialities List
- the insurer pays according to that framework, rather than the patient simply deciding whether the medicine is worth its full market price
That creates a classic third-party-payer problem.
If someone needs to personally pay CHF 10,000 for a treatment, they are extremely price-sensitive. If an insurer pays most of that CHF 10,000, the end-users demand for the treatment can remain relatively insensitive to its price.
That potentially gives the supplier greater pricing power.
But Switzerland has an interesting twist
It isn't actually an unrestricted "charge whatever you want" system. The FOPH uses two principal pricing comparisons:
Therapeutic comparison — what comparable medicines already cost in Switzerland.
International comparison — what the same medicine costs in nine European reference countries (Germany, France, UK, Netherlands, Sweden, Denmark, Austria, Belgium and Finland).
So there is a regulatory mechanism specifically designed to prevent an unrestricted price.
But here's where the hypothesis becomes interesting.
The FOPH itself currently acknowledges that Switzerland has the highest medicine prices and highest per-capita medicine costs among European countries.
It also says that the cost of new medicines added to the reimbursement list has risen disproportionately, with their average prices now more than 50% higher than ten years ago.
And medicines accounted for approximately CHF 9.2 billion of Swiss outpatient basic-health-insurance expenditure in 2024, roughly one-fifth of total basic-insurance costs.
So there is a real phenomenon here that is clearly worth investigating.
Where "price-rigging" becomes a different question
We should distinguish three things:
A. High prices
A company charges CHF 1,000 when comparable countries pay CHF 700.
B. Strategic pricing
The company deliberately sets its Swiss price high because it knows that compulsory insurance substantially reduces the consumer's sensitivity to that price.
C. Price fixing/rigging
Two or more companies, or companies and other actors, deliberately coordinate prices or manipulate the market rather than independently setting prices.
A doesn't establish B, and B doesn't establish C.
The evidence we've found establishes that Switzerland has unusually high pharmaceutical prices and that the government is actively concerned about the cost. It doesn't, by itself, demonstrate illegal price coordination.
There is another fascinating incentive
Switzerland's system can potentially make the reimbursement negotiation itself extremely important.
A pharmaceutical company isn't simply asking: "What price will Swiss consumers tolerate?" It's effectively asking: "What maximum reimbursable price can we negotiate with the Swiss system?"
And the answer matters because being placed on the reimbursement list gives the company access to a population whose treatment is substantially financed through compulsory insurance.
The government itself says that the FOPH sets the maximum price that basic insurers will pay.
That means access to the insurance system and the price negotiated with it are economically intertwined.
And there's a particularly revealing statistic
The Swiss government says: medicines are contributing to rising basic-health-insurance premiums.
It explicitly states that rising drug prices feed into insurance premiums because premiums follow healthcare costs.
So there is a potentially circular structure:
Pharmaceutical price → insurance expenditure → insurance premiums → compulsory payments by households
The consumer ultimately bears part of the cost, but not necessarily at the moment when the purchasing decision is made.
That's precisely the kind of structure economists examine when studying moral hazard, third-party payment and supplier pricing power.
And then comes promotion
Getting a medicine approved doesn't automatically mean doctors will prescribe it. Pharmaceutical companies therefore invest heavily in commercialisation.
This can include:
- information provided to healthcare professionals
- scientific conferences
- medical education
- permitted advertising
- patient information
- disease-awareness campaigns
- digital communications
- sales representatives
- market-access activities
- publication of clinical evidence
But pharmaceutical promotion is regulated. Swissmedic monitors medicinal-product advertising, including print, television, electronic media and online/social-media activity.
It can intervene where advertising is misleading, makes unsupported claims, implies guaranteed effectiveness or suggests that a medicine has no side effects.
This is important because pharmaceutical marketing isn't simply ordinary consumer advertising. A pharmaceutical advertisement can influence medical decisions.
Prescription medicines are a special case
The promotional environment becomes particularly interesting with prescription medicines. Swiss rules restrict promotional practices surrounding prescription-only medicines.
The Federal Office of Public Health notes that promotional measures can include corporate-image promotion, disease-awareness campaigns and information campaigns connected to prescription-only medicines, and that benefits or compensation associated with such measures can fall under specific legal restrictions.
In other words, there is a legal distinction between: providing legitimate medical information and providing incentives intended to influence prescribing, dispensing or purchasing.
The distinction matters because the pharmaceutical industry's customer isn't always the person swallowing the medicine.
In many cases, the chain is: Pharmaceutical company → doctor → patient → insurer
The patient may ultimately use the product, but someone else may choose it and someone else may pay for it.
That makes pharmaceutical marketing fundamentally different from selling chocolate or watches.
The enormous importance of doctors
A pharmaceutical company's commercial success can depend on whether doctors believe a medicine is useful.
That means scientific evidence becomes commercially important.
Clinical trial results can influence:
- regulatory approval
- treatment guidelines
- doctors' prescribing decisions
- reimbursement decisions
- hospital purchasing
- public perception
- investor expectations
This creates a complicated relationship between science and commerce.
The industry needs scientific credibility because its products depend on evidence. But successful commercialisation can generate enormous financial rewards.
That doesn't automatically mean the science is bad. Nor does profitability automatically mean a medicine is unnecessary.
It means there are two systems operating simultaneously: medical value and commercial value.
The difficult question is where they overlap — and where they diverge.
Switzerland's pharmaceutical industry also makes money for Switzerland
The benefits aren't restricted to pharmaceutical shareholders. Companies employ people. Workers pay income taxes. Universities receive research funding.
Interpharma estimates that its member companies generated CHF 4.4 billion in Swiss sales in 2024 while paying around CHF 5 billion in taxes and levies and investing CHF 9.1 billion in research and development.
The association estimates that the industry contributes up to CHF 10 billion annually to Swiss public revenues and supports around 50,000 direct and 250,000 indirect jobs.
Those are industry-association estimates, rather than independent government accounting, so they should be treated as such.
But there is independent evidence of the industry's enormous economic importance.
Swiss pharmaceutical exports alone were CHF 114.5 billion in 2024, according to figures cited by Interpharma from Swiss official statistics.
The multiplier effect
This is where the Swiss strategy becomes particularly clever. Imagine a pharmaceutical company employing 10,000 people. Those people don't exist in isolation.
They need: houses, restaurants, transport, computers, laboratories, etc. The pharmaceutical sector therefore creates demand throughout the wider economy.
Interpharma's economic study estimates that the pharmaceutical industry generated CHF 74.5 billion of gross value added in Switzerland in 2022 and was associated with approximately 250,200 indirect jobs in addition to around 50,600 direct jobs.
Again, those multiplier estimates come from industry-commissioned economic analysis and should not be confused with a direct government count.
But the underlying mechanism is straightforward. High-value industry creates high-value supporting industries.
The other side of the equation
There is another way of looking at the pharmaceutical economy. The industry generates enormous wealth partly because medicines can command high prices.
That creates an unavoidable public debate. A new treatment can be genuinely innovative and potentially life-changing while simultaneously being extraordinarily expensive.
The question then becomes: Who should pay?
Patients? Private insurers? Government? Compulsory health insurance? Employers indirectly through insurance premiums? Taxpayers?
Or pharmaceutical companies through lower prices?
There isn't a single universally accepted answer.
The Swiss government itself acknowledges the tension between innovation and access. Its health policy states that intellectual property can encourage pharmaceutical research while also recognising that intellectual-property mechanisms are one factor contributing to medicines being unaffordable for some people.
This is one of the central contradictions of modern pharmaceuticals.
The same patents that can encourage investment in new medicines can also contribute to temporary market exclusivity and higher prices.
Switzerland's dependence on pharmaceuticals
The economic relationship works both ways. Switzerland benefits enormously from pharmaceuticals. But that means pharmaceuticals also matter enormously to Switzerland.
In 2025, chemicals and pharmaceuticals accounted for CHF 152 billion of Swiss exports — 53% of the country's merchandise exports.
That is an extraordinary concentration in a single broad industrial category.
It helps explain why Swiss governments have repeatedly tried to maintain conditions attractive to pharmaceutical research and investment.
The Federal Council's biomedicine strategy explicitly sought to strengthen Switzerland's biomedical research and technology environment across the entire value chain — from development and authorisation through to market access.
The programme was originally launched in 2013 and a second package followed in 2022.
The strategy demonstrates something important: Switzerland's pharmaceutical success isn't accidental.
It has been supported by deliberate economic and regulatory policy.
But Switzerland isn't simply a giant drug factory
This is perhaps the biggest misconception. Some of the country's pharmaceutical value comes from manufacturing. But much of the wealth comes from intellectual property, research, development, finance and global commercialisation.
A molecule discovered in a Swiss laboratory may eventually be manufactured in several countries. A Swiss pharmaceutical company may conduct trials internationally.
Its products may be sold almost entirely outside Switzerland and its shareholders may be scattered around the world. Its revenues may be earned in dollars, euros, yen and dozens of other currencies.
Yet the company can still generate substantial economic activity inside Switzerland.
That is the extraordinary feature of the model. Switzerland has effectively become one of the world's command centres for pharmaceutical value creation.
The Roche example
Roche provides perhaps the clearest illustration. Founded in Basel in 1896, the company remains deeply rooted in Switzerland. But its business is global.
In 2025:
Group sales: CHF 61.5 billion
Pharmaceutical sales: CHF 47.7 billion
Core operating profit: CHF 21.8 billion
Core R&D investment: CHF 12.2 billion
Pharmaceutical R&D: approximately CHF 10.4 billion.
And Roche continued investing in Switzerland. In 2025 it announced a CHF 500 million investment in a new research and development centre in Basel.
This demonstrates the cycle:
Research
↓
Clinical development
↓
Regulatory approval
↓
Intellectual property
↓
Manufacturing
↓
Global sales
↓
Revenue
↓
More R&D
↓
New medicines
The machine continually attempts to feed itself.
What happens when a medicine fails?
This is an important part of the story that is often forgotten. Most potential medicines do not become blockbuster products. Companies can spend years and vast sums on candidates that ultimately fail because they:
- don't work well enough
- have unacceptable side effects
- cannot be manufactured economically
- fail clinical trials
- cannot compete with existing treatments
- cannot secure regulatory approval
- or become commercially unattractive
The successful medicines therefore have to compensate for enormous investment in unsuccessful ones. This is one reason pharmaceutical economics can look unusual compared with ordinary manufacturing.
A company isn't simply paying to manufacture something people already want. It is effectively gambling billions on which scientific ideas will eventually work.
The patent clock
There is another complication. A pharmaceutical patent does not necessarily mean a company receives the full patent term of pure commercial sales. Years can pass between discovery, patenting, clinical development and regulatory approval.
That means companies have a strong incentive to move medicines through development efficiently.
Once exclusivity eventually ends, competitors may enter with generic or biosimilar versions depending on the product and applicable rules.
Prices can then fall dramatically.
This produces another race:
discover → patent → develop → approve → launch → maximise value during exclusivity → replace the product before competition arrives.
For large pharmaceutical companies, maintaining the pipeline is therefore essential.
Why Switzerland?
The final question is perhaps the most revealing.
Why would pharmaceutical companies choose Switzerland when medicines can theoretically be developed almost anywhere?
The answer is that Switzerland offers a combination of factors:
- Scientific expertise
- Political stability
- Strong intellectual-property protection
- Highly skilled labour
- Universities and research institutions
- Specialist manufacturing
- A mature financial system
- A dense life-sciences cluster
- Access to European markets
- A reputation for precision and reliability
And perhaps most importantly: an ecosystem that already exists. A pharmaceutical company doesn't merely choose a country. It chooses an environment.
Switzerland has spent more than a century building that environment.
The pharmaceutical paradox
There is a deeper story underneath Switzerland's success. The country's pharmaceutical industry demonstrates both the strengths and tensions of modern capitalism.
On one side, enormous amounts of private capital are converted into scientific research, exports generate enormous wealth, tax revenues support the state, and research attracts more researchers.
The economic ecosystem becomes self-reinforcing.
On the other side, successful medicines can become enormously profitable, patents temporarily restrict competition, prices can become politically contentious, and companies have commercial incentives to maximise sales.
Patients can find themselves caught between the value of a treatment and its cost.
Switzerland's real pharmaceutical export
Switzerland's greatest pharmaceutical export may therefore not be the pill itself. It is the entire system required to create the pill.
The country has built an environment in which:
science creates discoveries
↓
companies turn discoveries into candidates
↓
clinical researchers test them
↓
regulators evaluate them
↓
patents protect successful inventions
↓
manufacturers produce them
↓
marketing organisations commercialise them
↓
health systems pay for them
↓
global customers create revenues
↓
profits and investment finance the next generation of research
Switzerland sits unusually close to the centre of that entire chain.
And that helps explain how a country with no significant oil reserves, no huge domestic market and no coastline became one of the world's wealthiest economies.
It didn't need to own the world's resources. It learned to monetise knowledge.
The bottom line
Switzerland's pharmaceutical success is not simply a story about producing medicines. It is a story about capturing value at almost every stage of the pharmaceutical lifecycle.
The country provides the scientists, the research environment, the companies, the specialist suppliers, the clinical infrastructure, the regulatory system, and the financial environment.
The companies then sell their products to the world.
In 2025, that model helped chemicals and pharmaceuticals generate CHF 152 billion in Swiss exports, more than half of the country's total merchandise exports.
That makes Switzerland's pharmaceutical industry far more than a successful business sector. It is one of the foundations of the Swiss economic model.
And perhaps the most revealing feature is this: Switzerland doesn't need to consume what it produces.
It needs the rest of the world to buy it.
That is how a small country in the middle of the Alps turned scientific knowledge into one of the world's most valuable export industries.
Read more on:
Pharmaceuticals in Britain's rivers
The Solution to Pollution is Not Dilution
When Banks Become Landlords, Who Gets Left Out?
Peacekeepers or Occupiers? Secret ISF Documents Will Reveal Hidden Strategic Plan
The Bildeberg Group: Secrets of the Elite
Comments
Post a Comment